Buy & Sell Teradyne, Inc. (TER) – Teradyne, Inc. Price Today
Aura AI Summary
Key Stats
- $59.87BMarket Cap
- TechnologySector
- -26.73%3M Drawdown
- $59.71BEnterprise Value
- 0.14%Dividend Yield
- 56% Buy | 44% SellTrading Activity
- 34 daysTypical Hold Time
Teradyne, Inc. (TER) is currently valued at a market capitalization of $59.87B, with an enterprise value of $59.71B. Over the past 52 weeks, Teradyne, Inc. has traded between a low of $75.09 and a high of $418.08, highlighting its annual price range. Over the past three months, Teradyne, Inc. has recorded a drawdown of -26.73%, reflecting recent price volatility. Teradyne, Inc. offers a dividend yield of 0.14%, with the most recent dividend of $0.13 paid on 13 Feb 26. On average, investors hold Teradyne, Inc. for approximately 34 days, indicating typical investor behavior on the platform.
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Most Recent News
CallPhantom scam apps on Google Play fake call logs but charge real money, downloaded 7.3M+ times.
ESET researchers uncovered 28 fraudulent Android apps named CallPhantom on Google Play that falsely claim to provide call logs, SMS, and WhatsApp history for any phone number in exchange for payment. These apps, downloaded over 7.3 million times, gen...
Oculis secures FDA agreement on trial design for Privosegtor in optic neuritis treatment
Oculis Holding AG has received FDA Special Protocol Assessment (SPA) approval for its Phase 3 PIONEER-1 trial of Privosegtor, a novel neuroprotective drug for optic neuritis (ON). This agreement confirms the trial design is suitable to support a futu...
Pakistan’s HBL launches Temenos Core Banking, modernizing 40M accounts across 200 branches.
Habib Bank Limited (HBL) in Pakistan has successfully implemented Temenos Core Banking, marking a major modernization effort. The initial phase migrated accounts from 200 branches, supporting both Conventional and Islamic banking. Once fully deployed...